Cargando…
Substance P Antagonism Prevents Chemotherapy-Induced Cardiotoxicity
SIMPLE SUMMARY: Anthracyclines are a class of chemotherapeutics that are an essential component of many treatment regimens for solid and blood tumors. Doxorubicin (DOX), an anthracycline is broadly considered the most active single agent available for many cancers. However, effective use of anthracy...
Autores principales: | Legi, Ashiq, Rodriguez, Emma, Eckols, Thomas K., Mistry, Cyrus, Robinson, Prema |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038801/ https://www.ncbi.nlm.nih.gov/pubmed/33917491 http://dx.doi.org/10.3390/cancers13071732 |
Ejemplares similares
-
Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance
por: Robinson, Prema, et al.
Publicado: (2016) -
Substance P Causes Seizures in Neurocysticercosis
por: Robinson, Prema, et al.
Publicado: (2012) -
Substance P—Friend or Foe
por: Robinson, Prema, et al.
Publicado: (2022) -
Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis
por: Rodriguez, Emma, et al.
Publicado: (2021) -
Substance P Receptor Antagonism: A Potential Novel Treatment Option for Viral-Myocarditis
por: Robinson, Prema, et al.
Publicado: (2015)